as 09-12-2025 4:00pm EST
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
To train our stocks EVAX ML model, we use historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other metrics.
We update our ML model either weekly or biweekly, depending on the market capitalization of the stocks, using TensorFlow, typically over the weekend.
Unfortunately, our current data provider offers limited historical data, which impacts the accuracy of our ML model. However, as we continue to gather more data over time and add more indicators, we expect the accuracy of our model to improve.
We would greatly appreciate your contribution. Please send an email to info@finquota.com
Yes, we offer it for strategy purposes only, with intervals: 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes etc.
Our ML model is primarily designed for educational purposes and is not intended to provide financial advice. We strongly recommend consulting with a financial advisor before making any buying or selling decisions.
Our EVAX ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"EVAX Forecast & Prediction for September 13, 2025 Evaxion Biotech" should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.